MONSENSO A/S Company announcement no. 07-2024
This message includes inside information
The Board of Directors of Monsenso A/S hereby announces the decision to issue warrants for employees and management, who are in a non-terminated position and who were employed on
The vesting period for the warrants is 36 months from
The Board of Directors has set the exercise price at
The warrant holder shall not pay any compensation for the granting of the warrants. The vested warrants can be exercised twice a year after publication of the company's annual and half-yearly report in an exercise window of pt. 2 weeks.
Monsenso's share capital amounts to a nominal value of
Any inquiries regarding this notice should be directed to:
Monsenso
CEO
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com
Chairman of the board
E-mail: Petermorcheriksen@outlook.com
Certified Adviser
Norden CEF A/S
E-mail: jn@nordencef.dk
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com
Attachments
- Download announcement as PDF.pdf
© Ritzau Denmark, source
